Life imprisonment

First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant

Retrieved on: 
måndag, maj 6, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, USD, Anticoagulant, Hemostasis, Stroke, TIMI, Anthos, Risk, DOAC, MD, Doctor of Philosophy, Pharmacist, AZALEA, Patient, Professional, Atrial fibrillation, Therapy, Life imprisonment, Thrombosis, Rivaroxaban, Pharmaceutical industry

Results of the first-ever cost-effectiveness study of a Factor XI inhibitor were presented today during sessions of the Professional Society for Health Economics and Outcomes Research (ISPOR) annual meeting.

Key Points: 
  • Results of the first-ever cost-effectiveness study of a Factor XI inhibitor were presented today during sessions of the Professional Society for Health Economics and Outcomes Research (ISPOR) annual meeting.
  • The analysis indicates that abelacimab could offer a potential cost-savings of $50,000 USD and improvements of 1.5 quality-adjusted life years (QALY’s) per person over a lifetime horizon as compared to rivaroxaban, a commonly used direct oral anticoagulant (DOAC).
  • If approved by US regulatory authorities, abelacimab could be a highly cost-effective anticoagulant option.
  • The great promise of a factor XI inhibitor such as abelacimab, rests largely with the ability to prevent thrombosis with minimal disruption of hemostasis.

The geko™ device is now available through the NHS Supply Chain

Retrieved on: 
onsdag, maj 1, 2024
Leg, Supply, Pain, Patient, Knee, Cancer, BMJ Open, NHS, Acceleration, Calf, DOI, Hope, National Health Service, Hospital, Skin, PMID, SOC, Recurrence, Common fibular nerve, Carbon, INT, IWJ, Quality-adjusted life year, Mouth ulcer, Nursing, Health, Cardiovascular disease, Standard of care, Wound healing, RCT, Life imprisonment, Quality of life, Anxiety

HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain. The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.

Key Points: 
  • HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain .
  • The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.
  • "We're delighted to be listed on the NHS Supply Chain," said Bernard Ross, CEO and Founder of Sky Medical Technology.
  • Now with this wider access, through the NHS Supply Chain, geko device ease of ordering will further help NHS wound care nurses reduce the time managing wounds."

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
torsdag, mars 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

North Carolina Humanities Announces New Support for North Carolina Reads

Retrieved on: 
tisdag, februari 27, 2024
McGuireWoods, Circus, Library, Culture, Humanities, History, Life imprisonment, Heart, Gender, Baseball, Poster, Book

North Carolina Reads is North Carolina Humanities' statewide book club that annually features five books that explore issues of racial, social, and gender equity and the history and culture of North Carolina.

Key Points: 
  • North Carolina Reads is North Carolina Humanities' statewide book club that annually features five books that explore issues of racial, social, and gender equity and the history and culture of North Carolina.
  • The North Carolina Reads program invites readers across North Carolina to read the selected books and then join North Carolina Humanities' monthly virtual book club discussions to hear directly from book authors and topic experts.
  • At the heart of North Carolina Reads is North Carolina Humanities' desire to connect communities through shared reading experiences.
  • North Carolina Humanities Board Chair Mike Wakeford said, "We are grateful to McGuireWoods for their support of North Carolina Reads.

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Retrieved on: 
onsdag, januari 17, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Diabetes, Patient, Therapy, Quality-adjusted life year, SOC, Society, Digital, Type 2 diabetes, American Diabetes Association, Better, Cognitive behavioral therapy, Advances in Therapy, ICER, A1C, QALY, Life imprisonment, Prevalence, Pharmaceutical industry

The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.

Key Points: 
  • The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.
  • This suggests that the use of AspyreRx can empower patients to better manage their diabetes with the potential for lifelong advantages.
  • This latest study modeled the cost-effectiveness of AspyreRx plus SoC versus SoC alone in T2D over a lifetime horizon.
  • "The publication of this data, demonstrating that adding AspyreRx to standard of care has the potential to be more effective and less costly than standard of care alone, exemplifies our vision to make societies healthier and meaningfully reduce healthcare costs.”

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Retrieved on: 
tisdag, oktober 17, 2023
Nexus, Food, Expo Hall, T2D, Standard of care, QALY, Risk, Hospital, Orlando World Center Marriott, Death, Mortality, AMCP, Academy of Managed Care Pharmacy, HF, FDA, ED, Heart failure, Quality-adjusted life year, National meetings of the Workers' Party of Korea, Cypress, Life imprisonment, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, SOC, Patient, Health insurance, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023, at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, Orlando, Florida.

Key Points: 
  • The budget impact was modeled as the change in medical and pharmacy costs from using sotagliflozin in addition to the standard of care (SoC) compared with the SoC alone among U.S. patients hospitalized with heart failure (HF).
  • Costs included pharmacy, inpatient, emergency department visits, and other medical and adverse event costs.
  • Amongst treated patients on sotagliflozin, commercial payers incurred increased pharmacy costs of $7,276 per patient per year as compared to patients on SoC alone.
  • Clinical outcomes of interest were hospital readmissions, emergency department (ED) visits, and all-cause deaths after an HF hospitalization.

International Self-Care Day: Better Self-Care, Better Healthcare; Better Welfare Globally

Retrieved on: 
måndag, juli 24, 2023
International, Life imprisonment, COVID-19, Ageing, Health policy, Non-governmental organization, Universal health care, Health, UHC, WHO, Universal, Health insurance

And today, on International Self-Care Day, the Global Self-Care Federation (GSCF) is calling for all stakeholders to back the urgent adoption of a WHO resolution on self-care.

Key Points: 
  • And today, on International Self-Care Day, the Global Self-Care Federation (GSCF) is calling for all stakeholders to back the urgent adoption of a WHO resolution on self-care.
  • It is imperative to preserve the momentum and empower individuals to manage their own health while while lessening burdens on health systems globally.
  • International Self-Care month is recognised annually between June 24th - July 24th, is part of the WHO's global health calendar.
  • The United for Self-Care Coalition is calling for all supporters to take up the call for a WHO resolution on self-care:

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

Retrieved on: 
fredag, augusti 4, 2023
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, HU, Ruxolitinib, Medical Affairs Bureau, Senior, Hydroxycarbamide, Life imprisonment, Ropeginterferon alfa-2b, Case Comprehensive Cancer Center, Quality of life, National Comprehensive Cancer Network, Quality-adjusted life year, Journal of Comparative Effectiveness Research, Polycythemia vera, PV, MS, NCCN, QALY, Journal, Peginterferon alfa-2a, Journal of the National Comprehensive Cancer Network, Polycythemia, Patient, HIV disease progression rates, Risk, Phlebotomy, Treatment, Hematology, Mortality, TES, Myeloproliferative neoplasm, Safety, News, MPN, Pharmaceutical industry, MD

The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.

Key Points: 
  • The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.
  • Cost effectiveness was demonstrated in a modeled population including both low- and high-risk patients receiving first- or second-line treatment with ropeginterferon alfa-2b-njft.
  • Findings from the study conclude ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea.
  • “Ropeginterferon alfa-2b-njft has demonstrated safety and efficacy in studies including both low- and high-risk patients and patients with and without prior cytoreductive treatment with HU.

EQS-News: Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis

Retrieved on: 
torsdag, juni 22, 2023
Science, Partnership, Civil service commission, Life imprisonment, Clinical trial, Technische Hochschule, SL, Multiple sclerosis, Bristol Myers Squibb, Translation, MS, IHI, Patient, European Commission, Disease, Pharmaceutical industry, European

The project, launched at the start of June, has total funding of almost 10 million Euros, contributed by industry partners and the European Commission and will run over the next four years.

Key Points: 
  • The project, launched at the start of June, has total funding of almost 10 million Euros, contributed by industry partners and the European Commission and will run over the next four years.
  • The goal is to develop a companion diagnostic platform supporting the assessment of disease worsening in patients with multiple sclerosis (MS), making data-driven precision medicine a reality for this group.
  • “MS is a devastating and highly unpredictable disease that affects everyone differently with a continued high need for effective and safe treatments.
  • The diversity of the consortium is a true asset, ensuring all necessary expertise is available to achieve its challenging goals.

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Retrieved on: 
onsdag, maj 3, 2023
Health, Medical Devices, Diabetes, Health Technology, General Health, Clinical Trials, Pharmaceutical, CGM, Hypoglycemia, Blood, Probability, National Health Service, Type 2 diabetes, IQVIA, Life imprisonment, Fear, Quality of life, Hyperglycemia, Multimedia, Research, Quality-adjusted life year, QALY, Risk, DXCM, Patient, NHS, Engineered wood, Pharmaceutical industry, Dexcom, Glycated hemoglobin

The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.

Key Points: 
  • The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.
  • The cost-effectiveness of Dexcom rtCGM was sensitive to capture the quality of benefits associated with reduced fear of hypoglycaemia and avoidance of testing with finger pricks, as well as the HbA1c benefit associated with rtCGM use1.
  • Patients using rtCGM were assumed to have a 0.56% reduction in HbA1c based on the mean difference between groups after 12 months of follow-up.
  • Reduced fingerstick testing when using rtCGM was associated with a quality of life (QoL) benefit.